Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans
JCSM Rapid Communications2021Vol. 4(2), pp. 232–244
Citations Over Time
Alyssa Marie M. Castillo, Trang T. Vu, Sophia G. Liva, Min Chen, Zhiliang Xie, Justin Thomas, Bryan Remaily, Yizhen Guo, Uma L. Subrayan, Travis Costa, Timothy H. Helms, Donald Irby, Kyeongmin Kim, Dwight H. Owen, Samuel K. Kulp, Thomas A. Mace, Mitch A. Phelps, Christopher C. Coss
Abstract
These data demonstrate increases in catabolic clearance of monoclonal antibodies observed in humans can be replicated in cachectic mice, in which Fcgrt expression is also reduced. Notably, FcRn activity is essential for proper antigen presentation and antitumour immunity, which may permit the study of cachexia's impact on FcRn-mediated clearance and efficacy of ICI therapies.
Related Papers
- → Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab(2019)19 cited
- → <p>Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer</p>(2020)16 cited
- → Risk of cumulative toxicity after complete melanoma response with pembrolizumab(2017)8 cited
- → Out-of-hospital ventricular fibrillation in three adolescents(2008)1 cited
- → Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies(2020)1 cited